Does the media favor OGN or ANRO?

In the previous week, Alto Neuroscience had 3 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Alto Neuroscience and 2 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.32 beat Alto Neuroscience's score of 0.30 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alto Neuroscience 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TARS or ANRO?

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 5 mentions for Alto Neuroscience. Tarsus Pharmaceuticals' average media sentiment score of 0.33 beat Alto Neuroscience's score of 0.30 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alto Neuroscience 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ARQT or ANRO?

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Alto Neuroscience. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 5 mentions for Alto Neuroscience. Arcutis Biotherapeutics' average media sentiment score of 0.54 beat Alto Neuroscience's score of 0.30 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RGC or ANRO?

Alto Neuroscience has a consensus target price of $37.25, indicating a potential upside of 55.21%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts clearly believe Alto Neuroscience is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alto Neuroscience 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Which has preferable earnings and valuation, RGC or ANRO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A

Is RGC or ANRO more profitable?

Regencell Bioscience's return on equity of 0.00% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Alto Neuroscience N/A -46.46% -39.09%

Does the media favor RGC or ANRO?

In the previous week, Alto Neuroscience had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Alto Neuroscience and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.69 beat Alto Neuroscience's score of 0.30 indicating that Regencell Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ANRO or MOR?

Alto Neuroscience presently has a consensus price target of $37.25, suggesting a potential upside of 55.21%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts plainly believe Alto Neuroscience is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Alto Neuroscience (ANRO) Competitors

$25.02 +0.99 (+4.12%)

As of 01:12 PM Eastern

Compare

ANRO vs. OGN, TARS, ARQT, RGC, and MOR

Should you buy Alto Neuroscience stock or one of its competitors? Alto Neuroscience's main competitors and comparable companies include Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), Arcutis Biotherapeutics (ARQT), Regencell Bioscience (RGC), and MorphoSys (MOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alto Neuroscience compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 17.25%. Alto Neuroscience has a consensus target price of $37.25, suggesting a potential upside of 55.21%. Given Alto Neuroscience's stronger consensus rating and higher probable upside, analysts plainly believe Alto Neuroscience is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Organon & Co. has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.89
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Organon & Co. has a net margin of 3.41% compared to Alto Neuroscience's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Alto Neuroscience	N/A	-46.46%	-39.09%

Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

In the previous week, Alto Neuroscience had 3 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Alto Neuroscience and 2 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.32 beat Alto Neuroscience's score of 0.30 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alto Neuroscience	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Organon & Co. beats Alto Neuroscience on 10 of the 15 factors compared between the two stocks.

How does Alto Neuroscience compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alto Neuroscience has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	7.02	-$66.42M	-$1.09	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Tarsus Pharmaceuticals has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Alto Neuroscience has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Alto Neuroscience	N/A	-46.46%	-39.09%

Tarsus Pharmaceuticals presently has a consensus target price of $100.86, indicating a potential upside of 39.65%. Alto Neuroscience has a consensus target price of $37.25, indicating a potential upside of 55.21%. Given Alto Neuroscience's higher probable upside, analysts plainly believe Alto Neuroscience is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.70
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 5 mentions for Alto Neuroscience. Tarsus Pharmaceuticals' average media sentiment score of 0.33 beat Alto Neuroscience's score of 0.30 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alto Neuroscience	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tarsus Pharmaceuticals beats Alto Neuroscience on 9 of the 16 factors compared between the two stocks.

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Arcutis Biotherapeutics has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.19	-$16.14M	$0.21	116.62
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Arcutis Biotherapeutics has a net margin of 6.15% compared to Alto Neuroscience's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Alto Neuroscience	N/A	-46.46%	-39.09%

In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Alto Neuroscience. MarketBeat recorded 9 mentions for Arcutis Biotherapeutics and 5 mentions for Alto Neuroscience. Arcutis Biotherapeutics' average media sentiment score of 0.54 beat Alto Neuroscience's score of 0.30 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

Arcutis Biotherapeutics currently has a consensus price target of $36.00, indicating a potential upside of 47.00%. Alto Neuroscience has a consensus price target of $37.25, indicating a potential upside of 55.21%. Given Alto Neuroscience's higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.70
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Arcutis Biotherapeutics beats Alto Neuroscience on 11 of the 13 factors compared between the two stocks.

How does Alto Neuroscience compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Regencell Bioscience has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

Alto Neuroscience has a consensus target price of $37.25, indicating a potential upside of 55.21%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts clearly believe Alto Neuroscience is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Regencell Bioscience's return on equity of 0.00% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Alto Neuroscience	N/A	-46.46%	-39.09%

In the previous week, Alto Neuroscience had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Alto Neuroscience and 2 mentions for Regencell Bioscience. Regencell Bioscience's average media sentiment score of 0.69 beat Alto Neuroscience's score of 0.30 indicating that Regencell Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alto Neuroscience beats Regencell Bioscience on 6 of the 11 factors compared between the two stocks.

How does Alto Neuroscience compare to MorphoSys?

Alto Neuroscience (NYSE:ANRO) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Alto Neuroscience has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

18.4% of MorphoSys shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alto Neuroscience has higher earnings, but lower revenue than MorphoSys. Alto Neuroscience is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Alto Neuroscience has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Alto Neuroscience's return on equity of -46.46% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-46.46%	-39.09%
MorphoSys	-226.79%	-694.31%	-22.55%

Alto Neuroscience presently has a consensus price target of $37.25, suggesting a potential upside of 55.21%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, analysts plainly believe Alto Neuroscience is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Alto Neuroscience had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Alto Neuroscience and 0 mentions for MorphoSys. Alto Neuroscience's average media sentiment score of 0.30 beat MorphoSys' score of 0.00 indicating that Alto Neuroscience is being referred to more favorably in the media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
MorphoSys	Neutral

Summary

Alto Neuroscience beats MorphoSys on 11 of the 15 factors compared between the two stocks.

Get Alto Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANRO vs. The Competition

Export

Metric	Alto Neuroscience	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$970.65M	$12.34B	$7.20B	$22.96B
Dividend Yield	N/A	2.65%	2.53%	3.72%
P/E Ratio	-10.22	797.65	274.63	28.59
Price / Sales	N/A	833.42	586.31	23.43
Price / Cash	N/A	86.17	76.82	36.46
Price / Book	5.08	10.64	10.93	4.71
Net Income	-$63.24M	$2.84B	$3.50B	$1.07B
7 Day Performance	-0.15%	-0.88%	-0.94%	0.33%
1 Month Performance	-27.24%	-5.76%	-5.45%	-3.82%
1 Year Performance	311.98%	-5.27%	4.43%	6.52%

Alto Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANRO Alto Neuroscience	2.5466 of 5 stars	$25.02 +4.1%	$37.25 +48.9%	+285.9%	$981.25M	N/A	N/A	68
OGN Organon & Co.	1.1284 of 5 stars	$13.75 +0.1%	$11.40 -17.1%	+34.4%	$3.61B	$6.22B	17.85	10,000
TARS Tarsus Pharmaceuticals	3.3198 of 5 stars	$76.69 -0.2%	$100.86 +31.5%	+3.5%	$3.37B	$451.36M	N/A	50	Analyst Downgrade
ARQT Arcutis Biotherapeutics	4.2453 of 5 stars	$26.75 -2.1%	$35.57 +33.0%	+15.3%	$3.36B	$376.07M	127.39	354	Analyst Forecast
RGC Regencell Bioscience	0.7003 of 5 stars	$6.20 flat	N/A	-60.7%	$3.07B	N/A	N/A	10	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANRO) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alto Neuroscience (ANRO) Competitors

ANRO vs. OGN, TARS, ARQT, RGC, and MOR

How does Alto Neuroscience compare to Organon & Co.?

Summary

How does Alto Neuroscience compare to Tarsus Pharmaceuticals?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Summary

How does Alto Neuroscience compare to Regencell Bioscience?

Summary

How does Alto Neuroscience compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alto Neuroscience (ANRO) Competitors

ANRO vs. OGN, TARS, ARQT, RGC, and MOR

How does Alto Neuroscience compare to Organon & Co.?

Do analysts prefer OGN or ANRO?

Which has stronger earnings and valuation, OGN or ANRO?

Do insiders and institutionals hold more shares of OGN or ANRO?

Is OGN or ANRO more profitable?

Which has more risk and volatility, OGN or ANRO?

Does the media favor OGN or ANRO?

Summary

How does Alto Neuroscience compare to Tarsus Pharmaceuticals?

Do institutionals and insiders believe in TARS or ANRO?

Which has higher earnings and valuation, TARS or ANRO?

Which has more risk & volatility, TARS or ANRO?

Is TARS or ANRO more profitable?

Do analysts rate TARS or ANRO?

Does the media favor TARS or ANRO?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Which has preferable valuation and earnings, ARQT or ANRO?

Is ARQT or ANRO more profitable?

Does the media prefer ARQT or ANRO?

Which has more risk and volatility, ARQT or ANRO?

Do analysts rate ARQT or ANRO?

Summary

How does Alto Neuroscience compare to Regencell Bioscience?

Which has more volatility & risk, RGC or ANRO?

Do analysts recommend RGC or ANRO?

Which has preferable earnings and valuation, RGC or ANRO?

Do insiders & institutionals believe in RGC or ANRO?

Is RGC or ANRO more profitable?

Does the media favor RGC or ANRO?

Summary

How does Alto Neuroscience compare to MorphoSys?

Which has more volatility and risk, ANRO or MOR?

Do insiders and institutionals hold more shares of ANRO or MOR?

Which has preferable earnings and valuation, ANRO or MOR?

Is ANRO or MOR more profitable?

Do analysts prefer ANRO or MOR?

Does the media prefer ANRO or MOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools